03/22/2021
CanWell, Sun Yat-sen Memorial Hospital of Sun Yat-sen University and UbiVac Jointly Held a Clinical Seminar on Cancer Vaccine DPV-001
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, together with CanWell and UbiVac, Inc., successfully held the First-in-Class International Symposium on Clinical Trials of Cancer Vaccine DPV-001 Vaccine. CanWell has obtained the exclusive license of UbiVac immunotherapy cancer vaccine DPV-00…
02/25/2021
CanWell and UbiVac Announce Exclusive License Agreement For Cancer Vaccine DPV-001 in Greater China
CanWell Pharma Inc., a leading venture-backed biopharmaceutical company developing innovative immunotherapies for cancer, and UbiVac, Inc., a US clinical stage immunotherapy company, today announced an exclusive license agreement to develop and commercialize UbiVac’s first-in-class cancer vaccine DP…